Clinical Case Series - 23CART2 - Question 1

What do you think is the best strategy for collaborative practice between community and CAR T-cell therapy sites?

The patient should be sent back to the community at day 30 with clear instructions for the community oncologist.

The patient should be sent back to the community at day 30, but with scheduled every-3-month visits at the CAR T-cell therapy site for the first year.

The patient should be managed by the CAR T-cell therapy administering site for the first 3 months, and then sent back to the community for monitoring, with continued follow-up at the CAR T-cell therapy site for the first year.

The patient should be managed by the CAR T-cell therapy administering site for up to 1 year and should be seen by the community as needed for interim monitoring at the direction of CAR T-cell therapy site.

{"name":"Clinical Case Series - 23CART2 - Question 1", "url":"https://www.poll-maker.com/QCVB1IMY0","txt":"What do you think is the best strategy for collaborative practice between community and CAR T-cell therapy sites?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}

Tools: Poll Maker | Quiz Maker | Super Surveys